Emzor Pharmaceuticals has unveiled plans to establish an Active Pharmaceutical Ingredients (API) facility in Sagamu, Ogun State, with a substantial investment totaling $23 million (over N25billion) in an effort to combat the pervasive threat of malaria in Nigeria and Sub-Saharan Africa.
Upon completion, the API facility will be the first anti-malarial API manufacturing plant in Nigeria and Africa, and it is expected to produce 400 metric tonnes of quality APIs annually, significantly accelerating the fight against malaria in Africa.
Background:
Recall that last October, during the EU-Nigeria Strategic Dialogue, the European Investment Bank (EIB) announced a €14 million funding to Emzor Pharmaceutical Industries Limited to accelerate the fight against malaria in Africa through the construction of the first antimalarial Active Pharmaceutical Ingredients (APIs) manufacturing plant in Nigeria.
The project will reduce Nigeria’s reliance on importing more than 90 percent of its APIs.
The plant will focus on producing high-quality and affordable anti-malarial drugs, marking a pivotal advancement in Africa’s healthcare sector.
Upon completion, the APIC facility is expected to produce 400 metric tonnes of quality APIs per year. It will also create over 500 jobs and expand into three more areas in the future.
Emzor Pharmaceuticals has also partnered with India’s Mangalam Drugs and Organics Limited for technology transfer training, testing, and initial production at the site.